Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector

McGettigan, James P.; Sarma, S.; Orenstein, Jan M.; Pomerantz, Roger J.; Schnell, Matthias J.

doi:10.1128/jvi.75.18.8724-8732.2001

Cited by 56 publications

(60 citation statements)

References 55 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single dose of J200 elicits CD8 + CMI following challenge with a heterologous viral vector (vv-Gag) up to 9 months later. The magnitude of the cellular immune response to J200 prime/vv-Gag challenge is similar in magnitude to prior observations with the most immunogenic attenuated viral vectors [52,66] and thus may also be effective at preventing advanced disease following pathogenic challenge. Further development of these Δγ 1 34.5 HSV vaccine vectors will include the incorporation of HIV-1 env with accessory genes and measuring the breadth of the immune response against a spectrum of CTL epitopes across the entire range of vaccine immunogens, rather than the single Gag epitope used in this study.…”

Section: Discussionsupporting

confidence: 80%

“…Some of these candidates have not yet been tested in humans but are non-toxic and elicit significant CMI responses in animal models. These include alphaviruses [55][56][57], polioviruses [58], and rhabdoviruses [52]. Candidate vaccine vectors in more advanced stages of development are under evaluation in human clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…This supports the hypothesis that the level of protective immune responses elicited by an antigen can be influenced by the delivery vector; in this case, an attenuated HSV. Persistent effect after a single dose has also been observed with other attenuated, replication competent vaccine vectors and this property may translate into enhanced vaccine efficacy [52,67,68].…”

Section: Discussionmentioning

confidence: 99%

“…injection with either a recombinant vaccinia virus (vv) that expresses HIV-1 Gag (vDK-1, referred to here as vv-Gag) or a vaccinia virus control (SC11, referred to as vv-only). Vaccinia virus replicates well in mice, and has been previously used to boost CTL responses after priming with HIV-1 Gag expressed from vaccine vectors in mice [52,53]. Splenocytes were harvested and Gag-specific CD8 + T cell responses were analyzed five days following vaccinia boost by stimulation with the MHC Class I-restricted Gag peptide AMQMLKETI and assessing IFN-γ production by intracellular cytokine staining.…”

Section: Gag-specific Cd8 + T Cell Responses In Mice Following Immunimentioning

confidence: 99%

See 3 more Smart Citations

HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice

Parker

Rottinghaus

Zajac

et al. 2007

Vaccine

View full text Add to dashboard Cite

We have constructed a replication competent, γ 1 34.5-deleted Herpes Simplex Virus type 1 (HSV-1) vector (J200) that expresses the gag gene from Human Immunodeficiency Virus type-1, primary isolate 89.6 (HIV-1 89.6 ), as a candidate vaccine for HIV-1. J200 replicates in vitro, resulting in abundant Gag protein production and accumulation in the extracellular media. Immunization of Balb/ c mice with a single intraperitoneal injection of J200 elicited strong Gag-specific CD8 responses, as measured by intracellular IFN-γ staining and flow cytometry analysis. Responses were highest between 6 weeks and 4 months, but persisted at 9 months post-immunization, the last time-point evaluated. These data highlight the potential utility of neuroattenuated, replication-competent HSV-1 vectors for delivery of HIV-1 immunogens.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Gag-specific Cd8 + T Cell Responses In Mice Following Immunimentioning

confidence: 99%

See 2 more Smart Citations

HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice

Parker

Rottinghaus

Zajac

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…However, probably due to their particulate nature, they also efficiently reach the MHC class I pathway in vivo. Proteins that assemble into VLPs derive from a variety of viruses, including HIV1 (16,20,21), rubella virus (22), human papillomavirus (15,23), Semliki Forest virus (24), RNA phages (25), and hepatitis B virus (6,25,26).…”

Section: Ajor Histocompatibility Complex Class I-and Mhcmentioning

confidence: 99%

Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles

Storni¹,

Lechner²,

Erdmann³

et al. 2002

The Journal of Immunology

113

111

View full text Add to dashboard Cite

Virus-like particles (VLPs) are known to induce strong Ab responses in the absence of adjuvants. In addition, VLPs are able to prime CTL responses in vivo. To study the efficiency of this latter process, we fused peptide p33 derived from lymphocytic choriomeningitis virus to the hepatitis B core Ag, which spontaneously assembles into VLPs (p33-VLPs). These p33-VLPs were efficiently processed in vitro and in vivo for MHC class I presentation. Nevertheless, p33-VLPs induced weak CTL responses that failed to mediate effective protection from viral challenge. However, if APCs were activated concomitantly in vivo using either anti-CD40 Abs or CpG oligonucleotides, the CTL responses induced were fully protective against infection with lymphocytic choriomeningitis virus or recombinant vaccinia virus. Moreover, these CTL responses were comparable to responses generally induced by live vaccines, because they could be measured in primary ex vivo 51Cr release assays. Thus, while VLPs alone are inefficient at inducing CTL responses, they become very powerful vaccines if applied together with substances that activate APCs.

show abstract

Live and Killed Rhabdovirus-Based Vectors as Potential Hepatitis C Vaccines

et al. 2002

View full text Add to dashboard Cite

A highly attenuated, recombinant rabies virus (RV) vaccine strain-based vector was utilized as a new immunization strategy to induce humoral and cellular responses against hepatitis C (HCV) glycoprotein E2. We showed previously that RV-based vectors are able to induce strong immune responses against human immunodeficiency virus type I (HIV-1) antigens. Here we constructed and characterized three replication-competent RV-based vectors expressing either both HCV envelope proteins E1 and E2 or a modified version of E2 which lacks 85 amino acids of its carboxy terminus and contains the human CD4 transmembrane domain and the CD4 or RV glycoprotein cytoplasmic domain. All three constructs stably expressed the respective protein(s) as indicated by Western blotting and immunostaining. Moreover, surface expression of HCV E2 resulted in efficient incorporation of the HCV envelope protein regardless of the presence of the RV G cytoplasmic domain, which was described previously as a requirement for incorporation of foreign glycoproteins into RV particles. Killed and purified RV virions containing HCV E2 were highly immunogenic in mice and also proved useful as a diagnostic tool, as indicated by a specific reaction with sera from HCV-infected patients. In addition, RV vaccine vehicles were able to induce cellular responses against HCV E2. These results further suggest that recombinant RVs are potentially useful vaccine vectors against important human viral diseases.

show abstract

Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector

Cited by 56 publications

References 55 publications

HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice

HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice

Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles

Live and Killed Rhabdovirus-Based Vectors as Potential Hepatitis C Vaccines

Contact Info

Product

Resources

About